A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

NCT05911217 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: CT041 autologous CAR T-cell injection

Sponsor

CARsgen Therapeutics Co., Ltd.

Collaborators

[object Object]